Environmental Epidemiology of Essential Tremor
特发性震颤的环境流行病学
基本信息
- 批准号:9009000
- 负责人:
- 金额:$ 84.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-03-01 至 2021-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceBiological MarkersBloodBradykinesiaBrainCase-Control StudiesClinicalCohort StudiesComplementComplexConsumptionCountryDevelopmentDietDiet ModificationDiseaseEnvironmental EpidemiologyEnvironmental Risk FactorEpidemiologic StudiesEpidemiologistEssential TremorEuropeFamily history ofFamily memberFirst Degree RelativeGenesGeneticGoalsHeadHistocompatibility TestingIncidence StudyIndividualIndolesInheritedIntention TremorInvestigationKnowledgeLaboratory AnimalsLeadLifeLinkManganeseMeatMediterranean DietMetabolicMetabolismNail plateNeurologistNeurotoxinsNew YorkNorth AmericaOrganOrganic solvent productParkinson DiseasePatientsPesticidesPublishingResearchResearch DesignRiskRisk FactorsRoleSamplingSampling StudiesSeveritiesSourceSpainSpousesTimeTissue SampleTissuesToxinTremorbasecase controlcohortfollow-uphigh riskhuman tissueinterestmodifiable riskprospectivepublic health relevancepyridineresponsestem
项目摘要
DESCRIPTION (provided by applicant): Our research is devoted to studying the causes of tremor, and especially essential tremor (ET), which is the most common type of tremor. Since 2000, we have been investigating whether several environmental neurotoxins are associated with ET. A link between harmane (HA) (1- methyl-9H-pyrido[3,4-b]indole) and ET has been emerging from these studies, which show that blood and brain HA concentration ([HA]) is elevated in ET cases (esp. familial ET) vs. control subjects. HA is a neurotoxin present in the diet (esp. in meat). Administration of HA to laboratory animals produces severe action tremor resembling ET. Yet the link between HA and ET has not been convincingly established. All epidemiological studies have been case-control studies; thus, it is not clear whether high blood [HA] precedes the onset of ET. Aim 1 of this proposal will address this issue. The HA story has also become more complex and multi-dimensional. Thus, we were recently intrigued to find that blood [HA] was higher in Parkinson's disease (PD) cases than controls in New York. HA is structurally similar to MPTP, a neurotoxin closely linked with PD. ET and PD are both tremor disorders; some patients develop both disorders (ET+PD; i.e., they are comorbid for the two conditions). Whether the HA - PD link is reproducible, whether it tracks with the subtype of PD in which tremor rather than bradykinesia/rigidity is the predominant feature, and whether biomarker findings from blood also occur in the target organ of interest (i.e., the brain) in PD is
not known. Aim 2 of this proposal will address this myriad of issues. Finally, whether individuals who are comorbid for both ET and PD have the highest blood [HA] is not known. Aim 3 of this proposal will address this issue. To close these gaps in knowledge, in this application, we propose a 5-year study with 3 inter-related aims that draw on several types of human tissue (blood, brain): AIM 1: To nail down the links between HA and ET by studying the association between baseline blood [HA] and the development of incident ET in a cohort study. AIM 2: To further solidify the emerging links between HA and PD by extending our observations to another country (Spain). AIM 3: To assess blood levels of HA in patients who have both ET and PD (ET+PD). This would be the only study heading in this direction - exploring the etiological role of
environmental factors, and more specifically toxins, in ET. It would thus complement the many ongoing studies searching for ET genes. The study could lead to the clear identification of the first modifiable risk factor for ET (i.e., dietary HA).This would also be the only study assessing the possible etiological role and tissue concentrations of this toxin, HA, which is structurally similar to MPTP, in patients with PD.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELAN D LOUIS其他文献
ELAN D LOUIS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELAN D LOUIS', 18)}}的其他基金
Clinical Pathological Study of Cognitive Impairment in Essential Tremor
特发性震颤认知障碍的临床病理学研究
- 批准号:
8758709 - 财政年份:2014
- 资助金额:
$ 84.79万 - 项目类别:
in Vivo Quantification of Cerebellar GABA and NAA in Essential Tremor
特发性震颤中小脑 GABA 和 NAA 的体内定量
- 批准号:
8613863 - 财政年份:2013
- 资助金额:
$ 84.79万 - 项目类别:
in Vivo Quantification of Cerebellar GABA and NAA in Essential Tremor
特发性震颤中小脑 GABA 和 NAA 的体内定量
- 批准号:
8734499 - 财政年份:2013
- 资助金额:
$ 84.79万 - 项目类别:
MILD PARKINSONIAN SIGNS AND THE RISK OF ALZHEIMER'S DISEASE
轻度帕金森病症状和阿尔茨海默病风险
- 批准号:
6827805 - 财政年份:2004
- 资助金额:
$ 84.79万 - 项目类别:
Pathogenesis Of Essential Tremor: Cerebellar Metabolism
特发性震颤的发病机制:小脑代谢
- 批准号:
7109212 - 财政年份:2003
- 资助金额:
$ 84.79万 - 项目类别:
Pathogenesis Of Essential Tremor: Cerebellar Metabolism
特发性震颤的发病机制:小脑代谢
- 批准号:
7277644 - 财政年份:2003
- 资助金额:
$ 84.79万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 84.79万 - 项目类别:
Fellowship Programs